ClinicalTrials.gg
CompletedNCT04567615Updated Jan 8, 2026Results posted

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

A Phase 2 interventional study of Nivolumab and Relatlimab in Hepatocellular Carcinoma, Hepatoma and Liver Cancer, Adult, sponsored by Bristol-Myers Squibb. Completed at 65 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.

Enrollment
9th of 53
266 · median 40
Started
2021
with 4 others
Phase 2
28 of 53
8 open now
Registered
35th of 53
by date
Lead sponsor
5 of 53
Bristol-Myers Squibb

Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 9th largest by enrollment, is one of 5 that started in 2021, is one of 28 in phase 2, and was the 35th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing nivolumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Hepatoma
  • Liver Cancer, Adult
  • Liver Cell Carcinoma
  • Liver Cell Carcinoma, Adult

Keywords

  • Hepatocellular Carcinoma
  • Advanced Hepatocellular Carcinoma
  • Liver Cancer
  • Liver Cancer, Adult
  • Liver Cell Carcinoma
  • Liver Cell Carcinoma, Adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmation
  • Must have advanced/ HCC
  • Have to be immunotherapy treatment-naive in the advanced/metastatic setting
  • Must have at least one (RECIST) v1.1 measurable untreated lesion
  • score of 5 or 6
  • (ECOG) performance status 0 or 1 for ECOG performance status scale

Key Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular cholangiocarcinoma
  • Prior organ allograft or bone marrow transplantation
  • No uncontrolled or significant cardiovascular disease
  • No active known disease
  • Have received one or two lines of tyrosine kinase inhibitor therapies
  • Evidence of radiographic progression on or after the last line of tyrosine kinase inhibitor therapy

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Arm A : Nivolumab

    Biological: Nivolumab

  • Experimental
    Arm B : Nivolumab + Relatlimab Dose 1

    Biological: Nivolumab · Biological: Relatlimab

  • Experimental
    Arm C : Nivolumab + Relatlimab Dose 2

    Biological: Nivolumab · Biological: Relatlimab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: OPDIVO, BMS-936558

  • BiologicalRelatlimab

    Specified dose on specified days

    Also known as: BMS-986016

06

What researchers measure

Primary outcomes

  1. Objective Response Rate(ORR) Assessed by BICR

    Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

Secondary outcomes

  1. Disease Control Rate Assessed by BICR

    Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  2. Duration of Response Assessed by BICR

    Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  3. Progression Free Survival(PFS) Assessed by BICR

    PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  4. Objective Response Rate Assessed by Investigator

    Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on investigator assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the investigator, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  5. Disease Control Rate Assessed by Investigator

    Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  6. Duration of Response Assessed by Investigator

    Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the investigator, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  7. Progression Free Survival(PFS) Assessed by Investigator

    PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  8. Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization to the date of death from any cause. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  9. Number of Participants With Adverse Events

    Number of participants with an Adverse Event. An Adverse Event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.

  10. Number of Participants With Serious Adverse Events

    Number of participants with Serious Adverse Events A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.

  11. Number of Participants With Adverse Events Leading to Discontinuation

    Number of participants with Adverse Events Leading to Discontinuation

    Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.

  12. Death Summary

    Number of participants who died.

    Time frame: From randomization to primary completion date (Approximately 29.5 Months)

  13. Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests

    Number of participants with clinical laboratory abnormalities in specific liver tests

    Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.

  14. Number of Participants With Clinical Laboratory Abnormalities in Thyroid Tests

    Number of participants with clinical laboratory abnormalities in thyroid tests

    Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.

07

Results

Posted Oct 8, 2024

Participant flow

Randomization
Participant flow — Randomization
MilestoneTreatment ATreatment BTreatment C
Started12811424
Completed12711324
Not completed110
Withdrew: Participant withdrew consent100
Withdrew: Adverse event unrelated to study drug010
Treatment Period
Participant flow — Treatment Period
MilestoneTreatment ATreatment BTreatment C
Started12711324
Completed310
Not completed12411224
Withdrew: Participant withdrew consent251
Withdrew: Death120
Withdrew: Lost to follow-up010
Withdrew: Participant no longer meets study criteria010
Withdrew: Disease progression856316
Withdrew: Study drug toxicity3104
Withdrew: Adverse event unrelated to study drug1161
Withdrew: Other reasons120
Withdrew: Still on-going treatment21222

Outcome measures

PrimaryObjective Response Rate(ORR) Assessed by BICR

Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Number · Percentage
Objective Response Rate(ORR) Assessed by BICR
PercentageTreatment ATreatment BTreatment C
Objective Response Rate(ORR) Assessed by BICR13.3 (7.9 to 20.4)10.5 (5.6 to 17.7)12.5 (2.7 to 32.4)
Statistical analysis
  • Treatment A vs Treatment B · Strata adjusted difference in orr: -2.7 · 95% CI -10.7 to 5.3Difference in ORR of Treatment B over ORR Treatment A
SecondaryDisease Control Rate Assessed by BICR

Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Number · Percentage
Disease Control Rate Assessed by BICR
PercentageTreatment ATreatment BTreatment C
Disease Control Rate Assessed by BICR44.5 (35.7 to 53.6)44.7 (35.4 to 54.3)33.3 (15.6 to 55.3)
SecondaryDuration of Response Assessed by BICR

Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Median · Months
Duration of Response Assessed by BICR
MonthsTreatment ATreatment BTreatment C
Duration of Response Assessed by BICR5.82 (5.55 to NA)NA (5.32 to NA)NA (7.39 to NA)
SecondaryProgression Free Survival(PFS) Assessed by BICR

PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Median · Months
Progression Free Survival(PFS) Assessed by BICR
MonthsTreatment ATreatment BTreatment C
Progression Free Survival(PFS) Assessed by BICR2.00 (1.91 to 3.75)2.00 (1.87 to 3.71)1.94 (1.74 to 3.71)
Statistical analysis
  • Treatment A vs Treatment B · Cox proportional hazard model: 1.00 · 95% CI 0.75 to 1.33HR of Treatment B over HR Treatment A
SecondaryObjective Response Rate Assessed by Investigator

Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on investigator assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the investigator, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Number · Percentage
Objective Response Rate Assessed by Investigator
PercentageTreatment ATreatment BTreatment C
Objective Response Rate Assessed by Investigator14.1 (8.6 to 21.3)13.2 (7.6 to 20.8)20.8 (7.1 to 42.2)
Statistical analysis
  • Treatment A vs Treatment B · Strata adjusted difference in orr: -0.9 · 95% CI -9.2 to 7.4Difference in ORR of Treatment B over ORR Treatment A
SecondaryDisease Control Rate Assessed by Investigator

Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Number · Percentage
Disease Control Rate Assessed by Investigator
PercentageTreatment ATreatment BTreatment C
Disease Control Rate Assessed by Investigator48.4 (39.5 to 57.4)50.9 (41.3 to 60.4)41.7 (22.1 to 63.4)
SecondaryDuration of Response Assessed by Investigator

Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the investigator, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Median · Months
Duration of Response Assessed by Investigator
MonthsTreatment ATreatment BTreatment C
Duration of Response Assessed by Investigator10.94 (4.63 to NA)NA (5.55 to NA)12.42 (3.61 to NA)
SecondaryProgression Free Survival(PFS) Assessed by Investigator

PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Median · Months
Progression Free Survival(PFS) Assessed by Investigator
MonthsTreatment ATreatment BTreatment C
Progression Free Survival(PFS) Assessed by Investigator3.32 (2.00 to 4.01)3.65 (1.97 to 4.30)1.94 (1.68 to 3.75)
Statistical analysis
  • Treatment A vs Treatment B · Cox proportional hazard model: 1.00 · 95% CI 0.75 to 1.33HR of Treatment B over HR of Treatment A
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time from randomization to the date of death from any cause. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment ATreatment BTreatment C
Overall Survival (OS)12.68 (9.40 to 18.76)12.19 (9.49 to 14.52)8.21 (4.76 to 16.92)
Statistical analysis
  • Treatment A vs Treatment B · Cox proportional hazard model: 1.05 · 95% CI 0.74 to 1.49HR of Treatment B over HR of Treatment A
SecondaryNumber of Participants With Adverse Events

Number of participants with an Adverse Event. An Adverse Event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsTreatment ATreatment BTreatment C
Number of Participants With Adverse Events11910822
SecondaryNumber of Participants With Serious Adverse Events

Number of participants with Serious Adverse Events A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsTreatment ATreatment BTreatment C
Number of Participants With Serious Adverse Events434614
SecondaryNumber of Participants With Adverse Events Leading to Discontinuation

Number of participants with Adverse Events Leading to Discontinuation

Time frame:
From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation
ParticipantsTreatment ATreatment BTreatment C
Number of Participants With Adverse Events Leading to Discontinuation13145
SecondaryDeath Summary

Number of participants who died.

Time frame:
From randomization to primary completion date (Approximately 29.5 Months)
Reported as:
Count of participants · Participants
Death Summary
ParticipantsTreatment ATreatment BTreatment C
Death Summary676018
SecondaryNumber of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests

Number of participants with clinical laboratory abnormalities in specific liver tests

Time frame:
From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
ParticipantsTreatment ATreatment BTreatment C
ALT OR AST> 5XULN25416
ALT OR AST> 10XULN7162
TOTAL BILIRUBIN > 2XULN17142
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN >2XULN WITHIN 30 DAYS14101
SecondaryNumber of Participants With Clinical Laboratory Abnormalities in Thyroid Tests

Number of participants with clinical laboratory abnormalities in thyroid tests

Time frame:
From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities in Thyroid Tests
ParticipantsTreatment ATreatment BTreatment C
TSH > ULN38422
TSH > ULN WITH TSH ≤ ULN AT BASELINE14181
TSH <LLN WITH TSH ≥ LLN AT BASELINE16262

Adverse events

Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose to primary completion date) : Approximately 29.5 months All-Cause mortality (From randomization to primary completion date): Approximately 29.5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A68/128 (53.1%)65/127 (51.2%)104/127 (81.9%)
Treatment B60/114 (52.6%)65/113 (57.5%)102/113 (90.3%)
Treatment C18/24 (75%)20/24 (83.3%)22/24 (91.7%)
Most frequent serious events
Showing 10 of 138
Most frequent serious events
EventTreatment ATreatment BTreatment C
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)29/12724/1136/24
MyocarditisCardiac disorders0/1271/1132/24
AscitesGastrointestinal disorders3/1273/1131/24
Colitis microscopicGastrointestinal disorders0/1270/1131/24
Oesophageal varices haemorrhageGastrointestinal disorders1/1270/1131/24
PancreatitisGastrointestinal disorders0/1270/1131/24
Multiple organ dysfunction syndromeGeneral disorders0/1270/1131/24
PyrexiaGeneral disorders2/1271/1131/24
HypersensitivityImmune system disorders0/1270/1131/24
COVID-19 pneumoniaInfections and infestations0/1270/1131/24
Most frequent other events
Showing 10 of 49
Most frequent other events
EventTreatment ATreatment BTreatment C
Aspartate aminotransferase increasedInvestigations33/12733/1133/24
AstheniaGeneral disorders16/1279/1137/24
AnaemiaBlood and lymphatic system disorders21/12716/1136/24
DiarrhoeaGastrointestinal disorders11/12720/1136/24
Alanine aminotransferase increasedInvestigations21/12727/1133/24
PruritusSkin and subcutaneous tissue disorders24/12716/1134/24
Oedema peripheralGeneral disorders17/12720/1132/24
AscitesGastrointestinal disorders6/12711/1134/24
Decreased appetiteMetabolism and nutrition disorders10/12715/1134/24
RashSkin and subcutaneous tissue disorders8/12712/1134/24

Baseline characteristics

All Randomized Participants

Age, Continuous
Age, Continuous(Years)Treatment ATreatment BTreatment CTotal
Mean64.0 ± 10.463.3 ± 11.268.1 ± 10.964.1 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ATreatment BTreatment CTotal
Female2321246
Male1059322220
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment ATreatment BTreatment CTotal
Hispanic or Latino1416030
Not Hispanic or Latino654715127
Unknown or Not Reported49519109
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment ATreatment BTreatment CTotal
White615412127
Black or African American2103
Asian2819249
American Indian or Alaska Native56011
Native Hawaiian or Other Pacific Islander0011
Other3508
Chinese1616436
Japanese74314
Malay0101
Asian Other68216
08

Study locations

65 sites
  • Local Institution - 0010
    Ciudad de Buenos Aires, Buenos Aires 1181, Argentina
  • Local Institution - 0019
    Buenos Aires, Distrito Federal C1096AAS, Argentina
  • Local Institution - 0017
    Rosario, Santa Fe Province S2002KDS, Argentina
  • Local Institution - 0063
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0025
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0060
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0016
    Barretos, São Paulo 14784400, Brazil
  • Unidade de Pesquisa Clínica do Hospital da Clínicas de Ribeirão Preto-Clinical Oncology
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • Local Institution - 0015
    São Paulo, São Paulo 01246-000, Brazil
  • Local Institution - 0024
    Temuco, Araucania 4800827, Chile
  • Local Institution - 0029
    Santiago, Santiago Metropolitan 000000, Chile
  • Local Institution - 0018
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0113
    Harbin, Heilongjiang 150081, China
  • Local Institution - 0114
    Changsha, Hunan 410013, China
  • Local Institution - 0118
    Xi'an, Shaanxi 710061, China
  • Local Institution - 0108
    Xi'an, Shan3xi 710126, China
  • Local Institution - 0107
    Shanghai, Shanghai Municipality 200032, China
  • Local Institution - 0117
    Hangzhou, Zhejiang 310016, China
  • Local Institution - 0048
    Brno, 65653, Czechia
  • Local Institution - 0047
    Hradec Králové, 50005, Czechia
  • Local Institution - 0046
    Prague, 140 59, Czechia
  • Local Institution - 0069
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
  • Local Institution - 0068
    Clichy, 92110, France
  • Local Institution - 0105
    Grenoble, 38043, France
  • Local Institution - 0074
    Lyon, 69004, France
  • Local Institution - 0067
    Pessac, 33600, France
  • Local Institution - 0077
    Hksar, 0, Hong Kong
  • Local Institution - 0079
    Shatin, 0, Hong Kong
  • Local Institution - 0072
    Matsuyama, Ehime 790-0024, Japan
  • Local Institution - 0054
    Yokohama, Kanagawa 232-0024, Japan
  • Local Institution - 0076
    Yokohama, Kanagawa 241-8515, Japan
  • Local Institution - 0045
    Ōsaka-sayama, Osaka 589-8511, Japan
  • Local Institution - 0075
    Ishikawa, 920-8641, Japan
  • Local Institution - 0071
    Kyoto, 602-8566, Japan
  • Local Institution - 0101
    San Luis Potosí City, San Luis Potosí 78250, Mexico
  • Local Institution - 0100
    Cuauhtémoc, 06700, Mexico
  • Local Institution - 0106
    Oaxaca City, 68020, Mexico
  • Local Institution - 0003
    Auckland, 1023, New Zealand
  • Local Institution - 0013
    Krakow, Lesser Poland Voivodeship 31-501, Poland
  • Local Institution - 0012
    Bytom, 41-900, Poland
  • Local Institution - 0009
    Mysowice, 41-400, Poland
  • Local Institution - 0039
    Warsaw, 02-034, Poland
  • Local Institution - 0038
    Craiova, Dolj 200542, Romania
  • Local Institution - 0037
    Bucharest, 022328, Romania
  • Local Institution - 0036
    Cluj-Napoca, 400015, Romania
  • Local Institution - 0070
    Suceava, 720214, Romania
  • Local Institution - 0001
    Singapore, Central Singapore 168583, Singapore
  • Local Institution - 0004
    Singapore, 308433, Singapore
  • Local Institution - 0011
    Seoul, Seoul-teukbyeolsi 05505, South Korea
  • Local Institution - 0020
    Seongnam-si, 13496, South Korea
  • Local Institution - 0043
    Seoul, 06351, South Korea
  • Local Institution - 0050
    Donostia / San Sebastian, Gipuzkoa 20014, Spain
  • Local Institution - 0066
    Barcelona, 08036, Spain
  • Local Institution - 0073
    Córdoba, 14004, Spain
  • Local Institution - 0051
    Madrid, 28009, Spain
  • Local Institution - 0049
    Madrid, 28041, Spain
  • Local Institution - 0058
    Pamplona, 31008, Spain
  • Local Institution - 0041
    Taichung, 40447, Taiwan
  • Local Institution - 0034
    Tainan, 704, Taiwan
  • Local Institution - 0031
    Taipei, 100, Taiwan
  • Local Institution - 0042
    Taipei, 11217, Taiwan
  • Local Institution - 0032
    Taoyuan, 333, Taiwan
  • Local Institution - 0089
    Ankara, 06230, Turkey (Türkiye)
  • Local Institution - 0090
    Edirne, 22030, Turkey (Türkiye)
  • Local Institution - 0091
    Kadiköy/Istanbul, 41380, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Aug 2023, 30 months.

Results were first posted in Oct 2024, 1 year 1 month after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 30 months is below that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Sep 28, 2020
StartActual
Feb 4, 2021
Primary completionActual
Aug 31, 2023
CompletionActual
Nov 19, 2025
Results first posted
Oct 8, 2024
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04567615
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
Feb 4, 2021
Primary completion
Aug 31, 2023
Completion
Nov 19, 2025
Results posted
Oct 8, 2024
Last update
Jan 8, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion